Ignite Creation Date:
2024-05-06 @ 1:31 AM
Last Modification Date:
2024-10-26 @ 11:06 AM
Study NCT ID:
NCT01839487
Status:
COMPLETED
Last Update Posted:
2020-07-20
First Post:
2013-04-22
Brief Title:
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer
Sponsor:
Halozyme Therapeutics
Organization:
Halozyme Therapeutics
Organization Data
Organization:
Halozyme Therapeutics
Class:
INDUSTRY
Study ID:
HALO-109-202
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Halozyme Therapeutics
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None